MTOR and hepatocellular carcinoma: Additionally, a postoperative immunosuppressive regimen based on mTOR inhibitors not only inhibits abnormal angiogenesis to reduce the risk of AVM recurrence (with a 20-year cumulative recurrence risk of 87%) but also does not increase the recurrence rate of HCC.